A variety of prosthetic blood pumps are currently undergoing experimental development or are available for clinical use. The Jarvik-7® and Jarvik 7-70® (Symbion-7® and Symbion 7-70®) total artificial hearts (TAH) have been used worldwide both experimentally and for clinical mechanical circulatory support. Of the 190 patients implanted with these devices, 133 went on to cardiac transplantation and 68 of the transplanted patients are alive. Complications associated with the use of the TAH have included postoperative hemorrhage, thrombosis with thromboembolism and infection. The incidence of infection in the patients implanted with the TAH has declined significantly since initial clinical use and is now near 30%. Staphylococcus epidermidis and Pseudomonas aeruginosa are the most commonly pathogens isolated from these devices.
BorovitzH.S., KormosR.L., GriffithB.P., HungT.. Clinical utilization of the artificial heart. Crit Rev Biomed Engineering1989; 17: 179.
2.
DidisheimP., OlsenD.B., FarrarD.J.Infections and thromboembolism with implantable cardiovascular devices. Trans Am Soc Artif Intern Organs1989; 35: 54–70.
3.
OlsenD.B.. Artificial heart registry, University of Utah.Artificial Heart Laboratory, 1991.
4.
Mc BrideL.R., SwartzM.T., ReedyJ.E., MillerL.W., PenningtonD.G.. Device related infections in patients supported with mechanical circulatory support devices for greater than 30 days. Trans Amer Soc Artif Intern Organs1991; 37: M258.
5.
KuninC.M., DobbinsJ.J., MeloJ.C.Infectious complications in four long-term recipients of the Jarvik-7 artificial heart. JAMA1988; 259: 860.
6.
MunerettoC., PavieA., SolisE.Special problems in use of the total artificial heart as a bridge to transplantation. Transplant Proc1989; 21: 2551.
7.
OaksT.E., PaeW.E., MillerC.A., PierceW.S.. Combined registry for the clinical use of mechanical ventricular assist pumps and the total artificial heart in conjunction with heart transplantation: fifth official report 1990. J Heart Lung Transplant1991; 10: 621.
8.
ReedyJ.E., SchwartzM.T., TermuhlenD.F.Bridge to transplantation: importance of patient selection. J Heart Transplant1990; 9: 473.
9.
DobbinsJ.J., JohnsonG.S., KuninC.M., DeVriesW.C.. Postmortem microbiological findings of two total artificial heart recipients. JAMA1988; 259: 865.
10.
DoughertyS.H., SimmonsR.L.. Infections in bionic man: the pathobiology of infections in prosthetic devices. Part. I. In: RavitchM.M., ed. Current problems in surgery.Chicago: Year Book Medical Publishers, Inc., 1982; 221.
11.
GoldmanP.A., HansenA.C., MohammadS.F., OlsenD.B.. Early results from flow measurements in the Utah-100 ventricle. Adv in Bioeng1991; 20: 477.
12.
GristinaA.G., DobbinsJ.J., GiammaraM.S., LewisJ.C., DevriesW.C.. Biomaterial-centered sepsis and the total artificial heart. JAMA1988; 259: 870.
LavelleJ.P., DuignanJ.P., NeliganM.C.. The effects of cardiopulmonary bypass on immune mechanisms of man. Irish J Med Sci1984; 153: 431.
15.
SabaT.M., and ScovillW.A.. Effect of surgical trauma on host defense. In: Nyhus LM, ed. Surgical annual. New York: Appleton-Century-Crofts, 1975; 7: 71.
16.
SladeM.S., SimmonsR.L., YunisE., GreenbergL.J.. Immunodepression after major surgery in normal patients. Surgery1975; 78: 363.
17.
Mc BrideL.R., RuzevichD., PenningtonD.G.Infectious complications associated with ventricular assist device support. Trans Amer Soc Artif Int Organs1987; 33: 201.
18.
WeidemannH., MullerK.M., HennigE., MeisslerM., BunzelM., BucherlE.S.. Infection and obstructive vegetative endocarditis after TAH replacement. Proc Europ Soc Artif Organs1986; 29–31.
19.
HamillR.J.. Role of fibronectin in infective endocarditis. Rev Infect Dis1987; 9: S360.
20.
MurrayK.D., HughesS., BearnsonD., OlsenD.B.. Infection in total artificial heart recipients. Trans Am Soc Artif Intern Organs1983; 24: 539.
21.
KielhofnerM.A., HamillR.J.. Role of adherence in infective endocarditis. Texas Heart Inst J1989; 16: 239.
MohammadS.F., TophamN.S., BurnsG.L., OlsenD.B.. Enhanced bacterial adhesion on surfaces pretreated with fibrinogen and fibronectin. Trans Amer Soc Artif Int Organs1988; 34: 573.
24.
BurnsG.L., OlsenD.B.. Thrombogenesis in and contiguous with pumping chambers. Ann NY Acad Science1987; 516: 663.
25.
LevinsonM.M., SmithR.G., CorkR.C.Thromboembolic complications of the Jarvik-7 total artificial heart: case report. Artif Organs1986; 10: 236.
26.
PantalosG.M., BurnsG.L., MohammadS.F.Microbiological survey of prosthetic blood pumps presterilization and poststerilization and at explant retrieval. Trans Amer Soc Artif Int Organs1989; 35: 702.
27.
RodbardS.. Blood velocity and endocarditis. Circulation1963; 27: 18.
28.
DobbinsJ.J., KirchnberG., DeVriesW.C.. The use of bacterial hybridization to determine the source of infection in a long term Jarvik-7 artificial heart recipient. In: NormanJ.C., ed. Cardiovascular science and technology, II.Louisville: Oxymoron Press, 1990; 227.
29.
KlainerA.S., PerkinsR.L.. Surface manifestations of antibiotic induced alterations in protein synthesis in bacterial cells. Antimicrob Agents Chemother1972; 1: 164.
30.
WardR.A., WellhausenS.R., DobbinsJ.J., JohnsonG.S., DeVriesW.C.. Thromboembolic and infectious complications of the total artificial heart implantation. Ann NY Acad Science, 1987; 516: 638.
